Ramucirumab
- Generic Name
- Ramucirumab
- Brand Names
- Cyramza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 947687-13-0
- Unique Ingredient Identifier
- D99YVK4L0X
- Background
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and down...
- Indication
Ramucirumab is indicated for the treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel for patients who progress after prior fluoropyrimidine- or platinum-containing chemotherapy. It is indicated, in combination with erlotinib, for the first-line treatment of metastatic no...
- Associated Conditions
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Non-Small Cell Lung Cancer, Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Associated Therapies
- -
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 85
- Registration Number
- NCT02572687
- Locations
- 🇺🇸
UCLA Medical Center, Santa Monica, California, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Washington University Medical Center, Saint Louis, Missouri, United States
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 29
- Registration Number
- NCT02564198
- Locations
- 🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸Texas Childrens Hospital, Houston, Texas, United States
🇺🇸Seattle Children's Hospital Research Foundation, Seattle, Washington, United States
A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 191
- Registration Number
- NCT02539225
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Toyonaka, Japan
🇨🇳For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-08-03
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 245
- Registration Number
- NCT02514551
- Locations
- 🇺🇸
Vista Oncology Inc. PS, Olympia, Washington, United States
🇨🇦For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Oshawa, Canada
🇺🇸Scott & White Memorial Hospital & Clinic, Temple, Texas, United States
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 164
- Registration Number
- NCT02443883
- Locations
- 🇺🇸
USC Norris Cancer Hospital, Los Angeles, California, United States
🇺🇸Carolinas Medical Center, Charlotte, North Carolina, United States
🇺🇸Arizona Clinical Research Center, Tucson, Arizona, United States
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 175
- Registration Number
- NCT02443324
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sutton, United Kingdom
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Tennessee Oncology PLLC, Nashville, Tennessee, United States
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 399
- Registration Number
- NCT02435433
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
🇨🇳"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Tainan, Taiwan
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 530
- Registration Number
- NCT02426125
- Locations
- 🇺🇸
Inova Comprehensive Cancer Care & Research Institute, Fairfax, Virginia, United States
🇺🇸Southeast Florida Hematology/Oncology, Fort Lauderdale, Florida, United States
🇺🇸University of Maryland- Biological Sciences, Baltimore, Maryland, United States
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
- Conditions
- Interventions
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 545
- Registration Number
- NCT02411448
- Locations
- 🇺🇸
UCLA Hematology/Oncology - Santa Monica, Los Angeles, California, United States
🇺🇸AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇯🇵Hyogo Prefectual Amagasaki General Medical Center, Amagashiki, Hyogo, Japan
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT02359058
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Ehime, Japan
🇯🇵For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician, Osaka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.